Author:
Helman Talia A.,Browne Brendan M.
Reference43 articles.
1. Prevalence of and racial/ethnic variation in lower urinary tract symptoms and noncancer prostate surgery in U.S. men;Platz;Urology (Ridgewood, N.J.),2002
2. Hemodynamic effects of once-daily tadalafil in men with signs and symptoms of benign prostatic hyperplasia on concomitant α1 -adrenergic antagonist therapy: results of a multicenter randomized, double-blind, placebo-controlled trial;Goldfischer;Urology (Ridgewood, N.J.),2012
3. Sildenafil citrate in combination with tamsulosin versus tamsulosin monotherapy for management of male lower urinary tract symptoms due to benign prostatic hyperplasia: A randomised, double-blind, placebo-controlled trial;Fawzi;Arab Journal of Urology,2017
4. Comparison in the efficacy of fesoterodine or mirabegron add-on therapy to silodosin for patients with benign prostatic hyperplasia complicated by overactive bladder: A randomized, prospective trial using urodynamic studies;Matsukawa;Neurourol Urodyn,2019
5. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia (BPH): AUA guideline amendment 2023;Sandhu;J Urol,2024